Study suggests pharmaceutical companies unfairly maintain high insulin costs through patenting processes

  • 📰 TIME
  • ⏱ Reading Time:
  • 30 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 39%
  • Publisher: 53%

Healthcare أخبار

Insulin,Pharmaceutical Companies,Patenting Processes

A new study reveals that pharmaceutical companies have been using patenting processes to unfairly maintain high insulin costs, adding to the financial burden faced by patients and insurers. The study highlights the role of the FDA's Orange Book and the U.S. Patent and Trademark Office in governing patent ownership and market competition.

The financial burden of high insulin costs that patients and insurers face is often blamed on the Food and Drug Administration’s (FDA) regulatory framework, but a new study suggests pharmaceutical companies have also been using patenting processes to unfairly maintain high costs.

In the FDA’s master list of approved medications, devices, and other therapeutics, a document known as the Orange Book, patent ownership of each item governs which companies are allowed to manufacture and sell which therapies. The FDA deals with drug approval, but patents are granted by another agency entirely, the U.S. Patent and Trademark Office (USPTO). Though there are rules governing which developments by pharmaceutical companies merit inclusion in the FDA’s Orange Book, experts have long said that the book remains full of improper patents that unfairly hamper market competitio

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 93. in SA

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين